A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Status: | Active, not recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/8/2019 |
Start Date: | September 11, 2013 |
End Date: | November 2020 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as
measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD)
through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT
will also be evaluated.
measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD)
through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT
will also be evaluated.
Participants will be followed for 5.5 years post-transplant for long-term safety via an
annual telephone contact.
annual telephone contact.
Inclusion Criteria:
- Participant is a CMV-seropositive HCT recipient
- Participant is planned to undergo either of the following:
- Sibling Donor Transplant
- Unrelated Donor Transplant
- Participant has one of the following underlying diseases:
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Acute undifferentiated leukemia (AUL)
- Acute biphenotypic leukemia
- Chronic myelogenous leukemia (CML)
- Chronic lymphocytic leukemia (CLL).
- A defined myelodysplastic syndrome(s) (MDS)
- Primary or secondary myelofibrosis
- Lymphoma (including Hodgkin's)
Exclusion Criteria:
- Participant has active CMV disease or infection or has received treatment for active
CMV disease or infection within 3 months (90 days) prior to transplant
- Participant has a modified hematopoietic cell transplant comorbidity index (HCT-CI)
score ≥ 4
- Participant has received a prior HCT and has residual Chronic Graft-versus-host
Disease (cGVHD)
- Participant who is scheduled to have a cord blood transplant or a haploidentical
transplant
- Participant has a platelet count of less than 50,000 mm3 within 3 days prior to
randomization (platelet transfusions are allowed)
- Participant has aplastic anemia or multiple myeloma
We found this trial at
31
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials